Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,320 recruiting studies in this area right now.
By phase
- Not applicable9,604
- Phase 24,428
- Phase 12,683
- Phase 1/Phase 21,650
- Phase 31,400
- Phase 2/Phase 3287
- Phase 4268
Top conditions
- Breast Cancer1,207
- Prostate Cancer646
- Cancer638
- Colorectal Cancer479
- Lung Cancer421
- Ovarian Cancer342
- Multiple Myeloma329
- Pancreatic Cancer288
- Gastric Cancer285
- Acute Myeloid Leukemia283
- Hepatocellular Carcinoma257
- Solid Tumor246
- Advanced Solid Tumor232
- Head and Neck Cancer228
- Cervical Cancer226
- Endometrial Cancer214
- Advanced Solid Tumors207
- Esophageal Cancer192
Leading sponsors
- M.D. Anderson Cancer Center455
- Fudan University305
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital128
Where studies are running
- California1,397
- Texas632
- Arizona508
- Florida436
- Alabama430
- New York405
- Massachusetts340
- Maryland331
- New Jersey275
- Pennsylvania235
Recruiting studies20,320 total
- NCT06666270RecruitingPhase 1
SYN818 for advanced solid tumors with DNA repair defects
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
Zhengzhou, HenanAges 18 years+ - NCT06771193Recruiting
Study of cervical cancer treatment patterns in Italy
This study looks at the types of treatments and disease characteristics in people with cervical cancer that is locally advanced (cannot be removed by surgery) or has come back or spread. It may help doctors understand how different treatments are used in Italy.
Bologna, BolognaAges 18 years+ - NCT06642220RecruitingPhase 2
Y-90 radioembolization for kidney cancer
This trial tests a procedure called Y-90 radioembolization for patients with kidney cancer tumors larger than 4 cm who cannot have or choose not to have surgery. The treatment delivers tiny radioactive beads through a blood vessel to the tumor to destroy cancer cells while limiting damage to healthy tissue.
London, OntarioAges 18 years+ - NCT06783348RecruitingPhase 2
Radioactive treatment for advanced kidney cancer
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
CaenAges 18–100 - NCT06788756RecruitingPhase 2/Phase 3
Testing L-Annamycin plus Cytarabine for relapsed AML
This trial tests whether the combination of two chemotherapy drugs, L-Annamycin and Cytarabine, can help adults whose acute myeloid leukemia (AML) has come back or not responded to one prior treatment. The goal is to see if this combination can lead to remission.
Birmingham, AlabamaAges 18–80 - NCT06786533RecruitingPhase 1
CAR-T cells for hard-to-treat AML
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
Houston, TexasAges 12 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT06783569RecruitingPhase 1
First-in-human study for advanced solid tumors
This trial tests a new experimental drug for people with advanced solid tumors that have not responded to standard treatments. It aims to find a safe dose and see if the drug can shrink tumors.
Harbin, Heiljiang ProvinceAges 18 years+ - NCT06784752RecruitingPhase 3
Testing a targeted radiation therapy for advanced neuroendocrine tumors
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Scottsdale, ArizonaAges 12–100 - NCT06788509Enrolling by invitationPhase 1
Continued treatment and safety monitoring after a parent study
This trial allows people who were already getting study treatment in a previous trial to keep receiving it and be monitored for safety. It is designed for those who have not had serious side effects or disease worsening.
Macquarie UniversityAges 18 years+ - NCT06792253RecruitingPhase 3
BEBT-908 plus rituximab for relapsed large B-cell lymphoma
This study tests a new drug, BEBT-908, combined with rituximab for people with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment that included a CD20 antibody. The goal is to see if this new combination works better than standard care.
Beijing, Beijing MunicipalityAges 18–75 - NCT06787105Recruiting
Fruquintinib for advanced colorectal cancer
This trial tests a drug called fruquintinib for people with advanced colorectal cancer that has spread. It is for patients who have already tried several standard treatments and need a new option.
Biberach, Baden-WurttembergAges 18 years+ - NCT06783647RecruitingPhase 2
LBL-024 combo for advanced solid tumors (NSCLC)
This trial tests a new drug combination for people with advanced non-small cell lung cancer or other solid tumors. It aims to see if adding LBL-024 to other treatments can help shrink tumors or slow their growth.
Hefei, AnhuiAges 18–75 - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT06792734RecruitingPhase 1
Testing BTM-3566 for lymphoma that has returned
This trial tests an experimental drug called BTM-3566 in people with a type of lymphoma that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Charlotte, North CarolinaAges 18 years+ - NCT06785818Recruiting
Long-term follow-up of Kymriah patients in South Korea
This study follows patients in South Korea who have already received Kymriah (tisagenlecleucel) in a real-world setting. It aims to monitor their long-term health and any side effects over time.
Bundang Gu, Gyeonggi-doAges birth–100 years - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06787612RecruitingPhase 2
New combination for platinum-resistant ovarian cancer
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
Birmingham, AlabamaAges 18 years+ - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
Gilbert, ArizonaAges 18 years+ - NCT06787183RecruitingPhase 2
Short-course radiation with chemoimmunotherapy for rectal cancer that has spread to the liver
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
Fuzhou, FujianAges 18–75 - NCT06788171RecruitingPhase 2
Combined therapy for colorectal cancer with liver spread
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
Fuzhou, FujianAges 18–75 - NCT06782971Recruiting
Testing a new combination for AML with high blast cells
This trial is testing a combination of venetoclax and azacitidine in people with acute myeloid leukemia (AML) who have a high percentage of blast cells (at least 20%) in their bone marrow or blood. It aims to see if this treatment approach can improve outcomes for patients regardless of previous treatments or transplant history.
Canberra, Australian Capital TerritoryAges 18 years+ - NCT03315468Recruiting
Melanoma patient study in France database
This study collects information from people with melanoma (skin cancer), at any stage. It may help researchers better understand melanoma and improve future care.
NantesAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,320 recruiting oncology studies from the U.S. registry right now, out of 31,393 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.